MONEY

MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 15, 2024 - 16:00
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
Read More

Tags:

Previous Article

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts...

Next Article

23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-M...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Israeli airstrikes rock Beirut, Hezbollah command centre hit

Israeli airstrikes rock Beirut, Hezbollah command centr...

Tomas Kauer - Mode... Sep 28, 2024

Wynn Resorts says it gets UAE's first gambling license

Wynn Resorts says it gets UAE's first gambling license

Tomas Kauer - Mode... Oct 5, 2024

Hewlett Packard Enterprise Announces Pricing of Public Offering of Mandatory Convertible Preferred Stock

Hewlett Packard Enterprise Announces Pricing of Public ...

Tomas Kauer - Mode... Sep 11, 2024